What are the complications of post‑transarterial chemoembolization (TACE) and how are they managed?

Complications of Post-TACE and Management

Post-embolization syndrome (fever, nausea, and pain) is the most common complication after TACE, occurring in the majority of patients, and should be managed with supportive care including antiemetics and analgesics; more serious complications like hepatic abscess, liver failure, and biliary injuries occur in approximately 5% of cases and require prompt recognition and intervention. 1, 2

Common Complications and Management

Post-Embolization Syndrome (Most Frequent)

The five most common adverse events following TACE are 2:

• Liver enzyme abnormalities (18.1%)
• Fever (17.2%)
• Haematological/bone marrow toxicity (13.5%)
• Pain (11%)
• Vomiting (6%)

Management approach:

• Supportive care with antiemetics and analgesics
• Consider intravenous steroids with antiemetics for 3 days at the time of TACE to reduce post-embolization syndrome incidence (though external validation is still needed) 2
• These symptoms are expected and self-limiting in most cases

Serious Ischemic Complications (4-5% incidence)

The following require immediate intervention 3, 4:

Hepatic or splenic abscess:

• Occurs in approximately 3 cases per 1000 procedures
• Management: US-guided drainage plus systemic antibacterial therapy 3
• Can be associated with sepsis requiring aggressive treatment 4

Acute cholecystitis:

• Results from non-target embolization of cystic artery
• Management: US-guided drainage or cholecystectomy depending on severity 3, 5

Bile duct necrosis/biloma:

• Presents with persistent fever and liver dysfunction
• Can manifest as stone-like hyperdensities in bile duct from necrotic tumor material 6
• Management: Endoscopic retrograde cholangiopancreatography (ERCP) for bile duct clearance or percutaneous drainage 5, 3

Duodenal perforation:

• Rare but life-threatening complication from non-target embolization
• Requires surgical intervention 5, 4

Life-Threatening Complications

Hepatic Failure (0.6% mortality rate)

• Most common cause of death after TACE 2
• Risk factors to identify before TACE:
  • Serum bilirubin >2 mg/dl 2
  • Tumor burden >50% of total liver volume 2
  • Child-Pugh C or decompensated Child-Pugh B cirrhosis 2
  • Impaired portal vein blood flow 2

Management: Intensive supportive care; prevention is key through proper patient selection

Tumor Rupture with Hemorrhage

• Unique complication requiring urgent recognition 7
• Management: Coil embolization of bleeding vessel; surgical intervention if embolization fails 7

Hepatic Artery Complications

• Hepatic artery occlusion (most frequent vascular complication) 4
• Hepatic artery spasm 4
• Management: Intra-arterial vasodilators for spasm; anticoagulation and close monitoring for occlusion

Special Populations and Considerations

Patients with Advanced Cirrhosis

TACE-DEB (drug-eluting beads) shows significantly higher rates of biliary injuries, intrahepatic bilioma, and global hepatic damage compared to conventional TACE in patients with advanced cirrhosis 2. Consider conventional TACE over TACE-DEB in this population.

Patients with Biliary-Enteric Anastomosis or Biliary Stent

These patients are at higher risk of hepatic abscess; other treatments should be preferred 2

Patients with Portal Vein Thrombosis

While traditionally contraindicated, selective TACE can be performed safely in segmental or sub-segmental portal vein obstruction if hepatopedal collateral flow is present 8. Avoid in main portal vein thrombosis due to increased risk of liver failure 9.

Critical Monitoring Parameters

Post-TACE surveillance should include:

• Clinical observation for fever, pain, and performance status
• Liver function tests (transaminases, bilirubin, albumin)
• Serum creatinine (particularly in patients with proteinuria ≥1+ or HbA1c ≥7%) 10
• Ultrasound and CT imaging to detect abscesses, bilomas, or other structural complications 3

Red flags requiring immediate intervention:

• Persistent fever beyond expected post-embolization syndrome duration
• Acute abdomen suggesting perforation or rupture
• Rapid deterioration in liver function
• Signs of sepsis

Prevention Strategies

Key measures to minimize complications 4:

• Super-selective catheterization of hepatic artery feeders to avoid non-target embolization 2
• Slow infusion of lipiodol
• Careful patient selection excluding those with contraindications
• Adjustment of chemotherapeutic dosage in high-risk patients
• Early detection through vigilant postoperative observation

Absolute contraindications to prevent catastrophic outcomes 8:

• Child-Pugh C cirrhosis
• ECOG performance status ≥2
• Main portal vein thrombosis with hepatofugal flow

The overall morbidity rate after TACE is reported as high as 23%, particularly in patients with HCC tumors >10 cm in diameter 1. However, with proper patient selection and technique, serious complications requiring intervention occur in only 4-5% of cases and do not worsen overall survival when managed appropriately 3.